{"id":"low-dose-zonisamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cognitive impairment"},{"rate":null,"effect":"Nephrolithiasis (kidney stones)"},{"rate":null,"effect":"Hypohidrosis (reduced sweating)"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide is a sulfonamide anticonvulsant that works through multiple mechanisms: it blocks voltage-gated sodium and T-type calcium channels to reduce neuronal excitability, and inhibits carbonic anhydrase to modulate pH-dependent neural activity. At low doses, these mechanisms provide anticonvulsant effects with potentially improved tolerability compared to standard dosing.","oneSentence":"Low-dose zonisamide reduces seizure activity by blocking sodium and calcium channels while inhibiting carbonic anhydrase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:22.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy)"},{"name":"Potentially Parkinson's disease or other neurodegenerative conditions (investigational at low doses)"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT01127165","phase":"PHASE4","title":"Low and High Dose Zonisamide in Children as Monotherapy","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2006-03","conditions":"Epilepsy","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low zonisamide"],"phase":"marketed","status":"active","brandName":"Low dose zonisamide","genericName":"Low dose zonisamide","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose zonisamide reduces seizure activity by blocking sodium and calcium channels while inhibiting carbonic anhydrase. Used for Epilepsy (adjunctive therapy), Partial seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}